Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 41

  • 497 clinical trials
  • 182 recruiting
  • 211 conditions
  • 25 countries

Conditions in this area

211 conditions with trials, the busiest first

Type 2 diabetes mellitus83Type 1 diabetes mellitus38Endocrine ophthalmopathy26Neuroblastoma26Obesity22Diabetes mellitus21Neuroendocrine tumour19Gastroenteropancreatic neuroendocrine tumour disease16Overweight16Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Chronic kidney disease8Adrenoleukodystrophy7Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+187

Clinical trials in Endocrine disorders

497 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

497 clinical trials

Type 2 diabetes mellitus+2

Not recruiting
Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Ly3437943 Sodium
  • Sponsor:Eli Lilly & Co.

Retinopathy proliferative

Not recruiting
Registered drug
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Dexamethasone Phosphate
  • Sponsor:Vaestra Goetalandsregionen

Type 2 diabetes mellitus

Not recruiting
InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Icodec
  • Sponsor:Novo Nordisk A/S

Diabetic retinopathy

Not recruiting
Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bi 764524
  • Sponsor:Boehringer Ingelheim International GmbH

Diabetes mellitus

Not recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Provention Bio Inc.

Pancreatic neuroendocrine tumour

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Neuroblastoma+5

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Capecitabine
  • Sponsor:Centre Oscar Lambret

Adrenal adenoma

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Metyrapone Bp
  • Sponsor:Medical University Of Vienna

Neuroendocrine carcinoma metastatic

Not recruiting
InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Human Adenovirus C Serotype 5 With E1 Gene Controlled By Chromogranin A Promoter And Hexon Modified With Protein Transduction Domain Motif
  • Sponsor:Uppsala University

Diabetic neuropathy+1

Not recruiting
Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Odm-111
  • Sponsor:Orion Corporation

Thyroid cancer

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Adrenoleukodystrophy

Not recruiting
Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leriglitazone
  • Sponsor:Minoryx Therapeutics S.L.

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide46 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsSodium Chloride13 clinical trialsCisplatin12 clinical trialsEtoposide12 clinical trialsMetformin Hydrochloride12 clinical trialsCarboplatin11 clinical trialsInsulin Glargine11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.